Influenza A Hemagglutinin H1 (A/Brisbane/59/2007) (H1N1) (Control peptide)

General information
 

Name:
Influenza A Hemagglutinin H1 (A/Brisbane/59/2007) (H1N1) (Control peptide)
Size:
50 μg
Catalog no:
X2623B
Price:
333 EUR
 

Additional extra details
 

  • Category

    Proteins & Peptides

    Long description

    nfluenza A virus is a major public health threat, killing more than 30,000 people per year in the USA (1). Novel influenza virus strains emerge periodically to which humans have little or no immunity, resulting in devastating pandemics. Influenza A can exist in a variety of animals; however it is in birds that all subtypes can be found (2). These subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. During 1997, an H5N1 avian influenza virus was determined to be the cause of death in 6 of 18 infected patients in Hong Kong (3). There was some evidence of human to human spread of this virus, but it is thought that the transmission efficiency was fairly low (4). Although it has been known that cleavage site and glycosylation patterns of the HA protein play important roles in determining the pathogenicity of H5 avian influenza viruses, it has only recently been shown that an additional glycosylation site within the globular head of the NA protein also contributes to the high virulence of the H5N1 virus (5).

    Antibody come from

    Synthetic peptide corresponding to 12aa in the N-terminus of the Hemagglutinin protein.

  • Other description

    Provided as solution in phosphate buffered saline with 0.02% sodium azide. Purified

    Clone

    not specified

    Antigen-antibody binding interaction

    Influenza A Hemagglutinin H1 (A/Brisbane/59/2007) (H1N1) (Control peptide)

  • Antibody is raised in

    see techfile

    Antibody's reacts with

    Human

    Antibody's reacts with these species

    This antibody doesn't cross react with other species

  • Antibody's specificity

    No Data Available

    Application

    ELISA

    Antibody's suited for

    Optimal concentration should be evaluated by serial dilutions.

  • Storage

    -20ºC

    Relevant references

    no information yet

    Protein number

    see ncbi

  • Warnings

    This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.

    Tissue

    control

    Virus

    influenza

  • Description

    Isotype or positive controls by peptides, antibodies and deactivated samples.Influenza A and B H1N1 H3N2 Hemagglutinin-nucleoprotein recombinant proteins, peptides and antibodies detect a virus commonly known as "the flu". Influenza is an infectious disease caused by an influenza virus. Symptoms can be mild to severe. The most common symptoms include a high fever, runny nose, sore throat, muscle pains, headache, coughing, and feeling tired. These symptoms typically begin two days after exposure to the virus and most last less than a week. The cough, however, may last for more than two weeks. In children, there may be nausea and vomiting, but these are not common in adults.Peptides short amino acid chains or epitopes or blocking antagonists. The shortest peptides are dipeptides, consisting of 2 amino acids joined by a single peptide bond, followed by tripeptides, tetra peptides, ... till polypeptides that are long, continuous, and unbranched synthetic peptide chains. These biological oligomers and polymers can be Solid-phase peptide synthesis (SPPS), or in continue produced for custom peptide synthesis projects. The High-efficiency solid phase peptide synthesis (HE-SPPS) is give very low production costs.